

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM705745

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Durect Corporation		12/21/2021	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Innocoll Pharmaceuticals Limited		
Street Address:	70 Sir John Rogerson's Quay		
City:	Dublin 2		
State/Country:	IRELAND		
Postal Code:	D02 R296		
Entity Type:	Corporation: IRELAND		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	4918452	POSIMIR	
CORRESPONDENCE DATA			
Fax Number:	2157012273		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2156657273		
Email:	cmiller@cozen.com		
Correspondent Name:	Camille M. Miller		
Address Line 1:	1650 Market Street, Suite 2800		
Address Line 2:	One Liberty Place		
Address Line 4:	Philadelphia, PENNSYLVANIA 19103		
DOMESTIC REPRESENTATIVE			
Name:	Camille M. Miller, Cozen O'Connor		
Address Line 1:	1650 Market Street		
Address Line 2:	One Liberty Place		
Address Line 4:	Philadelphia, PENNSYLVANIA 19103		
NAME OF SUBMITTER:	Camille M. Miller		
SIGNATURE:	/Camille M. Miller/		
DATE SIGNED:	02/01/2022		

OP \$40.00 4918452

Total Attachments: 2

source=Assignment - Durect to Innocoll#page1.tif

source=Assignment - Durect to Innocoll#page2.tif

CONFIRMATORY UNITED STATES TRADEMARK ASSIGNMENT

WHEREAS, Durect Corporation, a Delaware corporation having a place of business at 10260 Bubb Road, Cupertino, California 95014 (“DURECT”), is the owner of the United States trademark identified in Exhibit A and the associated trademark registration and/or application therefor and goodwill associated therewith existing in the United States (together the “Mark”); and

WHEREAS, Innocoll Pharmaceuticals Limited, a company incorporated in Ireland having company number 395965 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, D02 R296, Ireland (“INNOCOLL”) and DURECT are parties to that certain License Agreement dated 21 December 2021 (the “License Agreement”) pursuant to which DURECT assigned the Mark to INNOCOLL.

NOW, THEREFORE, in confirmation of such assignment and for good and valuable consideration provided under the License Agreement and the receipt and sufficiency of which are hereby acknowledged, DURECT assigns to INNOCOLL effective as of 21 December 2021 all right, title, and interest in and to the Mark, together with all (a) rights to file applications for and secure registrations thereof and to renew, extend, maintain, abandon or otherwise control the Mark and such associated applications, registrations and renewals, reissues, and extensions thereof in the United States of America, (b) all common law rights in the Mark, and (c) causes of action (including the right to bring suit for past infringement) arising from (a) and (b) and INNOCOLL accepts such assignment. For clarity, no right, title, or interest is granted or received with respect to any matter outside of the United States.

IN WITNESS WHEREOF, the Parties have caused their duly authorized representatives to execute this confirmatory assignment effective as of 21 December 2021.

Durect Corporation

By: Steve Helmer

Name: Steve Helmer

Title: VP, Chief Patent Counsel

Innocoll Pharmaceuticals Limited

By: Rebecca Bedno

Name: Rebecca Bedno

Title: Chief Legal & Compliance Officer

Exhibit A

Application/Registration Number	Mark	Jurisdiction
4,918,452	POSIMIR	United States only